Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

ecancermedicalscience editor's choice for May 2015

Targeted Intraoperative radiotherapy plus lumpectomy non-inferior to EBRT in preventing breast cancer recurrence

Final results of the HeartSpare study using the voluntary breath-hold technique treating breast cancer

Comment: ESTRO 2015 highlights

Comment: Metastatic triple-negative breast cancer responds to immunotherapy

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer

PARP inhibitor combo shows early promise for patients with and without BRCA mutations